Medtronic’s Insulin Pump Receives Regulatory Approva
The U.S. Food and Drug Administration has approved Medtronic's MiniMed Paradigm insulin pump, which is also a glucose monitor. This is the first device to deliver // insulin as well as monitor glucose levels in the blood. The MiniMed takes blood glucose every five minutes and gives 288 readings per day. It consists of two components, one of which is an electrode inserted under the skin....Medtronic Device Proves Effective in Parkinson’s Diseas
A recent study has shown that Medtronic Inc.'s (MDT) Activa brain stimulation device, in combination with medication is shown to improve motor functions// as well as quality of life in patients with advanced Parkinson's disease more than in patients receiving only medication. The study was published in Thursday's issue of the New England Journal of Medicine. In 2002 the F...Cables for Pre-sterilized Medtronic electrodes
Description:Unshielded...Medtronic Precision Plus System
Description:TUNA Therapy delivers low-level radiofrequency energy directly into hyperplasic prostate tissue while preserving the urethra and adjacent structures from harm. Twin needles deliver the RF energy, heating a precise area of tissue to produce significant coagulative necrosis. Adjustable shields covering the needles protect the urethra from thermal damage. The Precision Plus system is design...Medtronic Hall™ Mechanical Heart Valve
Description:Unique to the Medtronic Hall, the aortic and mitral valves are distinctly engineered to maximize performance. In the aortic position, the disc opens to 75 to maximize forward flow, while the mitral valve opens to 70 to minimize regurgitation. Designed to rotate within its sewing ring to allow the surgeon to align the leading edge of the disc parallel to blood flow and to avoid interference with...Medtronic Resting Heart™ System
Description:The Medtronic® Resting Heart System offers a new approach to reducing cardiac surgery morbidity....Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stent's Positive Clinical Profile
MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-year results fromthe Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positiveclinical profile of the Endeavor(R) drug-eluting coronary stent andbring to nearly 1,300 the number of Endeavor patients who have atleast two years of follow-up. Significantly, among those 1,300Endeavor patients, there have been no reported cases of late stentthr...